Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03257462 · ClinicalTrials.gov registry record · Phase 2
Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia
A Phase 2 study, sponsored by Spruce Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT03257462: Completed Phase 2 study, sponsored by Spruce Biosciences.
NCT03257462 is a Phase 2 study that has completed, run by Spruce Biosciences. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03257462, a Phase 2 study, has completed, sponsored by Spruce Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a multicenter Phase 2, multiple dose, dose escalation study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SPR001 in adult patients with classic congenital adrenal hyperplasia (CAH).
Primary Outcome
Incidence of treatment-emergent adverse events, changes from Baseline to End-of-study in clinical laboratory parameters, physical examination findings, vital signs, ECG parameters
Interventions
- DRUG SPR001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-07-12 |
| Est. Completion | 2019-03-29 |
| Phase | Phase 2 |
What the finished NCT03257462 record still lists
NCT03257462 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 1 intervention - of which SPR001 is the first listed.
NCT03257462 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03257462 about?
NCT03257462 is a clinical study titled "Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia". This is a multicenter Phase 2, multiple dose, dose escalation study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SPR001 in adult patients with classic congenital adrenal hyperplasia (CAH).
What is the current status of trial NCT03257462?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2017-07-12. Estimated completion is 2019-03-29.
What interventions are being tested in trial NCT03257462?
The interventions under investigation include: SPR001 (DRUG).
Who is sponsoring clinical trial NCT03257462?
This trial is sponsored by Spruce Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03257462's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI